Logo

Emma Millican, Harold Swerdlow

Nov 16, 2017

LGC has appointed Emma Millican as global NGS business unit manager and Harold Swerdlow as head of NGS technology development, positions the firm created to support the launch of its new NGS business unit. 

Millican was previously director of scientific operations at the Wellcome Trust Sanger Institute and prior to joining the Sanger Institute, she was the UK director of forensic and applied genetics at Eurofins.

Swerdlow joins LGC from the New York Genome Center, where he was vice president of sequencing. Previously, he was head of research and development at the Wellcome Trust Sanger Institute and also served as chief technology officer at the Dolomite Center.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.